Cytovale Deepens Sepsis Focus With Outcomes Data and SEP-1-Aligned Strategy

Cytovale, a diagnostics company focused on early sepsis risk detection, featured prominently this week for its efforts to expand its footprint in emergency departments through data-driven clinical and economic positioning. The company is centering its IntelliSep host-response test on triage and early decision-making, where sepsis identification is time-sensitive and financially consequential.

Cytovale is highlighting its presence at the SCCM 2026 conference in Chicago, where it will exhibit at Booth #318 and support a presentation on the impact of rapid sepsis test adoption across four emergency departments. The session, titled “Effect of Rapid Sepsis Test Adoption on Mortality, Discharge, Hospital-Free Days & Cultures in 4 EDs,” is expected to showcase real-world outcomes and operational metrics that are critical for hospital decision-makers.

The company also underscored real-world data from Froedtert Hospital showing a 42% reduction in mortality among ED patients with suspected infection following IntelliSep implementation. By tying its technology to measurable improvements in mortality, throughput, and hospital-free days, Cytovale is seeking to demonstrate both clinical value and tangible benefits for resource utilization and capacity management.

Parallel to its conference activities, Cytovale is aligning its strategy with evolving SEP-1 sepsis quality measures and related reimbursement pressures. Through an upcoming Becker’s Healthcare webinar, the company is linking early ED sepsis assessment to Value-Based Purchasing, hospital economics, and financial risk, while engaging leaders from notable health systems to reinforce its relevance to large provider organizations.

Across its communications, Cytovale emphasized workflow integration, including protocol assessment, lab setup, role-based training, and ongoing performance review to support IntelliSep adoption with minimal disruption. While no new product launches or contracts were disclosed, the combined focus on clinical outcomes, quality metrics, and thought leadership suggests a concerted push to position IntelliSep as a key tool in sepsis diagnostics and ED decision support.

Overall, the week presented Cytovale as deepening its engagement with emergency medicine and critical care stakeholders, using outcomes data and policy-aligned messaging to strengthen its market positioning and potential adoption trajectory in sepsis risk assessment.